AFFINITY AND TRANSCRIPTASE TECHNOLOGIES

Information

  • Research Project
  • 2869464
  • ApplicationId
    2869464
  • Core Project Number
    R43CA081958
  • Full Project Number
    1R43CA081958-01
  • Serial Number
    81958
  • FOA Number
    PAR-98-066
  • Sub Project Id
  • Project Start Date
    4/1/1999 - 25 years ago
  • Project End Date
    3/31/2001 - 23 years ago
  • Program Officer Name
    COUCH, JENNIFER A
  • Budget Start Date
    4/1/1999 - 25 years ago
  • Budget End Date
    3/31/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/19/1999 - 25 years ago
Organizations

AFFINITY AND TRANSCRIPTASE TECHNOLOGIES

DESCRIPTION: (Applicant's Description) One out of every three Americans will be afflicted with cancer in their life time. It is a devastating frightening disease which frequently ends in death after much suffering. Progress has been made in the treatment and cures of cancer but the progress has been incremental. Much time, effort, and expense has gone into research to understand and develop a cure for cancer but because of the complexity and resiliency of the disease, no "magic bullet" has been developed. The foregoing research has inspired the National Cancer Institute to develop the goal of obtaining a full set of complete cDNAs from normal, premalignant, and malignant cells to enable the molecular genetic events which predetermine, activate, and maintain malignancies to be determined. Once the differences in transcribed sequences are identified, the structure, activity, and function of the encoded protein(s) will be of prime importance. To provide the greatest utility, the cDNA libraries to be studied should contain complete cDNA clones so that once differences are ascertained, the clones may be directly used for expression and determination of the function of the encoded protein. The present application describes the development of CAP affinity enrichment and enhanced reverse transcriptase technologies which will significantly contribute to the successful establishment of full sets of complete cDNAs of normal and cancerous tissues. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
  • Organization Name
    ICOGENEX CORPORATION
  • Organization Department
  • Organization DUNS
    836856351
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98103
  • Organization District
    UNITED STATES